Tratamiento antibiótico para la infección pulmonar por micobacterias no tuberculosas en pacientes con fibrosis quística
Información
- DOI:
- https://doi.org/10.1002/14651858.CD010004.pub4Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 19 diciembre 2016see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Review
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Fibrosis quística y enfermedades genéticas
- Copyright:
-
- Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
| Roles and responsibilities | |
| TASK | WHO WILL UNDERTAKE THE TASK? |
| Protocol stage: draft the protocol | Valerie Waters |
| Review stage: select which trials to include (2 + 1 arbiter) | Valerie Waters and Felix Ratjen (+ Nikki Jahnke) |
| Review stage: extract data from trials (2 people) | Valerie Waters and Felix Ratjen |
| Review stage: enter data into RevMan | Valerie Waters |
| Review stage: carry out the analysis | Valerie Waters and Felix Ratjen |
| Review stage: interpret the analysis | Valerie Waters and Felix Ratjen |
| Review stage: draft the final review | Valerie Waters and Felix Ratjen |
| Update stage: update the review | Valerie Waters and Felix Ratjen |
Sources of support
Internal sources
-
No sources of support supplied
External sources
-
National Institute for Health Research, UK.
This systematic review was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane Cystic Fibrosis and Genetic Disorders Group.
Declarations of interest
None known.
Acknowledgements
The authors thank Dr Kenneth Olivier of the National Institutes of Health and National Institute of Allergy and Infectious Diseases for additional information regarding the Arikace® trial. We would also like to thank Nikki Jahnke for her assistance in the preparation of this review.
Version history
| Published | Title | Stage | Authors | Version |
| 2020 Jun 10 | Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis | Review | Valerie Waters, Felix Ratjen | |
| 2016 Dec 19 | Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis | Review | Valerie Waters, Felix Ratjen | |
| 2014 Dec 03 | Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis | Review | Valerie Waters, Felix Ratjen | |
| 2012 Dec 12 | Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis | Review | Valerie Waters, Felix Ratjen | |
| 2012 Jul 11 | Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis | Protocol | Valerie Waters, Felix Ratjen | |
Differences between protocol and review
1. Definition of NTM infection
In the protocol NTM infection was defined as "at least one respiratory specimen", this has been changed to the current definition which is the standard definition by the ATS of "at least two respiratory specimens positive by culture for NTM".
2. Secondary outcome measures
A sixth secondary outcome has been added "Quantitative sputum mycobacterial culture". This outcome was included in the original draft of the protocol, but removed following the advice of one of the peer reviewers and the contact editor. When the review authors looked at past and current ongoing RCTs for NTM lung disease, it became apparent that this is one of the main outcomes which is usually assessed and for the CF population (who may not be expected to convert their sputum), may be the most relevant. Hence the outcome has been listed again.
Keywords
MeSH
Medical Subject Headings (MeSH) Keywords
Medical Subject Headings Check Words
Humans;
